USFDA Guidance: Safety Reporting for Investigational Drugs and Devices & Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies
- Sharan Murugan
- 5 hours ago
- 3 min read
Safety reporting is one of the most critical safeguards in clinical trials involving investigational drugs and medical devices. To ensure that safety information is collected, evaluated, and communicated effectively, the U.S. Food and Drug Administration (FDA) has issued two complementary guidance documents:
Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices
Investigators are closest to trial participants and therefore play a critical role in identifying and reporting safety issues.
Reporting to Sponsors in IND Studies
Investigators must immediately report all serious adverse events to the sponsor, regardless of whether the event is considered drug-related. FDA interprets “immediately” to mean as soon as feasible, typically within one calendar day after the investigator becomes aware of the event.
The investigator’s report should include a detailed clinical description of the event and an assessment of whether there is a reasonable possibility that the investigational drug caused the event. While the sponsor makes the final causality determination, the investigator’s clinical judgment is a key input.
Reporting to Institutional Review Boards (IRBs)
Investigators must promptly report to the IRB any unanticipated problems involving risk to human participants or others. FDA considers safety information that meets IND safety reporting criteria to represent such unanticipated problems.
Some events may not meet the threshold for IND safety reporting but still require IRB notification, such as protocol deviations, medication errors, or breaches of confidentiality that affect participant safety.
Investigator Responsibilities in IDE Studies
For investigational device studies, investigators must report unanticipated adverse device effects to both the sponsor and the IRB as soon as possible, but no later than 10 working days after first learning of the event.
Investigators must also submit periodic progress reports, including safety information, at least annually.
Sponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies
Sponsors hold the primary responsibility for evaluating safety information across all trial sites and determining whether FDA reporting thresholds are met.
When Sponsors Must Submit IND Safety Reports
Sponsors must submit IND safety reports to FDA and all participating investigators when they identify:
serious and unexpected suspected adverse reactions,
findings from other studies (clinical, epidemiological, animal, or in vitro) that suggest a significant risk,
clinically important increases in the rate of expected serious suspected adverse reactions, or
safety findings that require changes to the protocol, investigator brochure, or informed consent.
Unexpected fatal or life-threatening suspected adverse reactions must be reported within 7 calendar days. All other reportable safety information must be reported within 15 calendar days.
Aggregate Safety Analysis: A Core Expectation for Sponsors
FDA strongly emphasises that many safety signals cannot be meaningfully interpreted from a single case. Sponsors are therefore expected to conduct aggregate analyses across:
multiple participants,
multiple trial sites, and
multiple studies within a development program.
Aggregate analysis is particularly important for adverse events that are anticipated in the study population, such as disease-related complications, cardiovascular events in older populations, or background hospitalisations.
Only when aggregate data show an imbalance suggesting a reasonable possibility of a causal relationship should expedited reporting occur.
Systematic Safety Surveillance Planning
Sponsors should prospectively develop a safety surveillance plan describing:
roles and responsibilities for safety review,
processes for individual and aggregate SAE evaluation,
anticipated serious adverse events that will be monitored in aggregate,
triggers for unblinding and aggregate review, and
measures to protect trial integrity.
This plan should evolve as more safety data become available and must be available for FDA inspection.
Maintaining Trial Integrity During Safety Reviews
When unblinded safety data are reviewed, FDA expects strict safeguards to prevent bias. Individuals reviewing unblinded aggregate data should be firewalled from those involved in trial conduct or efficacy analysis.
Data Monitoring Committees (DMCs) or other independent entities may be used to review unblinded safety data and provide recommendations to sponsors, while preserving trial integrity. For investigators and sponsors alike, understanding and operationalising these expectations is essential for compliant and ethical clinical development. For the most current and authoritative information, readers should consult the FDA guidance documents linked above.
Comments